NextCure, Inc. Files 8-K on Security Holder Vote Matters
Ticker: NXTC · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing
Related Tickers: NXTC
TL;DR
NextCure (NXTC) is holding a shareholder vote on June 20th.
AI Summary
On June 20, 2024, NextCure, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Delaware with its principal executive offices in Beltsville, Maryland, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates that NextCure, Inc. is engaging its security holders in a formal voting process, which could pertain to significant corporate decisions or governance changes.
Risk Assessment
Risk Level: low — The filing is a routine procedural report regarding a vote of security holders and does not disclose new financial or operational risks.
Key Numbers
- 001-38905 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-5231247 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Beltsville, Maryland (location) — Principal executive offices
- June 20, 2024 (date) — Date of earliest event reported
FAQ
What specific matters are being submitted for a vote by NextCure, Inc.'s security holders?
The filing states that the 8-K is for the 'Submission of Matters to a Vote of Security Holders,' but the specific details of these matters are not elaborated upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 20, 2024.
What is the principal business of NextCure, Inc. according to the filing?
NextCure, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where are NextCure, Inc.'s principal executive offices located?
The principal executive offices of NextCure, Inc. are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
What is the company's state of incorporation?
NextCure, Inc. is incorporated in Delaware.
Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-21 16:15:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Glo
Filing Documents
- nxtc-20240620x8k.htm (8-K) — 83KB
- 0001558370-24-009401.txt ( ) — 214KB
- nxtc-20240620.xsd (EX-101.SCH) — 4KB
- nxtc-20240620_def.xml (EX-101.DEF) — 3KB
- nxtc-20240620_lab.xml (EX-101.LAB) — 17KB
- nxtc-20240620_pre.xml (EX-101.PRE) — 12KB
- nxtc-20240620x8k_htm.xml (XML) — 5KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On June 20, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders: (i) elected the two Class II members of the Board, each to serve for a three-year term expiring at the Company's 2027 Annual Meeting of Stockholders and until such director's earlier death, resignation, or removal from the Board; (ii) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and (iii) did not approve a proposal to amend the Company's Amended and Restated Certificate of Incorporation to provide for the exculpation of Company officers. Set forth below are the voting results for each of the proposals voted upon by the Company's stockholders at the Annual Meeting. Proposal No. 1: Election of Class II Directors Nominee For Against Abstain Broker Non-Votes Elaine V. Jones, Ph.D. 11,788,402 1,722,327 2,402 8,403,929 Ellen G. Feigal, M.D. 12,945,547 565,182 2,402 8,403,929 Proposal No. 2: Ratification of Appointment of Ernst & Young as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 For Against Abstain Broker Non-Votes 21,818,499 98,189 372 - Proposal No. 3: Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to provide for the exculpation of Company officers 0 For Against Abstain Broker Non-Votes 10,638,433 2,863,486 11,212 8,403,929 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November Dated: June 21, 2024 NEXTCURE, INC. By: /s/ Steven P. Cobourn Name: Steven P. Cobourn Title: Chief Financial Officer